Abstract: A device for generating a source current of charge carriers by a field emission and a method stabilizing a source current of charge carriers emitted by a field emission element are disclosed. In an embodiment the device includes at least one field emission element from which the charge carriers emerge during operation, which lead to an emission current in the field emission element, at least one extraction electrode in order to extract the charge carriers from the field emission element, wherein a first part of the extracted charge carriers contributes to the source current, and a second part of the extracted charge carriers impinges on the extraction electrode and leads to an extraction current in the extraction electrode, an additional electrode on which the source current of charge carriers impinges at least in part and which contributes to an electrode current in the additional electrode.

Abstract: A receptacle holding unit for a beverage preparation device includes a first part and a second part cooperating with the first part; a cavity for receiving a receptacle containing an ingredient; and a driving device for relatively moving the second part towards the first part into a closed position for securing such receptacle in the cavity and relatively apart from the first part into an open position for inserting of the receptacle into the cavity. The driving device has an actuator and a transmission that has a helicoidal ramp arrangement cooperating with a connector member for converting a translational movement into a rotational movement or vice versa. When the actuator actuates the transmission, the first and second parts are driven together or apart by the ramp arrangement cooperating with the connector member.

Abstract: A braking device for a motor vehicle has a setpoint controlled deceleration device, which, upon receipt of a braking request input by a driver or an assistance system, for example, on the basis of a difference between a setpoint value and an actual value, drives a brake of the vehicle to generate a setpoint controlled braking torque for a deceleration of the motor vehicle. In addition, the braking device has a braking preparation control, which, upon receipt of a braking preparation signal, drives the brake independently of the setpoint value to produce at least one braking pressure for generating a preparation braking torque for a pre-deceleration of the motor vehicle. The braking preparation signal is generated as soon as a driving situation is ascertained where a braking request input by a driver or an assistance system is very likely imminent.

Abstract: The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.

Abstract: The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumour cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumour cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumour cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: (i) a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and (ii) a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.

Abstract: The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumor cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumor cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumor cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.

Abstract: The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N, CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).

Abstract: The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumor diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.

Abstract: A receptacle holding unit (1) for a device for preparing a beverage from an ingredient contained in a receptacle comprises: a first part (10) and a second part (20) cooperating with the first part; a cavity (11?) for receiving such receptacle, the cavity being delimited by at least one of the first and second parts; and a driving device (30) for relatively moving the second part towards the first part into a closed position for securing such receptacle in the cavity and relatively apart from the first part into an open position for inserting of the receptacle into the cavity. The driving device has an actuator (31) and a transmission (22, 32; 22?, 32?) that has a helicoidal ramp arrangement (32,32?) cooperating with a connector member (22,22?) for converting a translational movement into a rotational movement or vice versa.

Abstract: A receptacle holding unit (1) for a device for preparing a beverage from an ingredient contained in a receptacle comprises: a first part (10) and a second FIG. 3a part (20) cooperating with the first part; a cavity (11?) for receiving the receptacle, the cavity being delimited by at least one of the first and second parts; a driving device (30) for relatively moving the second part towards the first part into a closed position and relatively apart from the first part into an open position. The driving device comprising an actuator (31) and a transmission (22, 32; 22?, 32?) that has a helicoidal ramp arrangement (32,32?) cooperating with a connector member (22,22?) for converting a translational movement into a rotational movement or vice versa. The helicoidal ramp arrangement is mounted to the first part and the connector member is mounted to the second part so that, when the actuator actuates the transmission, the first and second parts are driven together or apart.

Abstract: The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N,CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).

Abstract: A braking device for a motor vehicle has a setpoint controlled deceleration device, which, upon receipt of a braking request input by a driver or an assistance system, for example, on the basis of a difference between a setpoint value and an actual value, drives a brake of the vehicle to generate a setpoint controlled braking torque for a deceleration of the motor vehicle. In addition, the braking device has a braking preparation control, which, upon receipt of a braking preparation signal, drives the brake independently of the setpoint value to produce at least one braking pressure for generating a preparation braking torque for a pre-deceleration of the motor vehicle. The braking preparation signal is generated as soon as a driving situation is ascertained where a braking request input by a driver or an assistance system is very likely imminent.

Abstract: A floor maintenance too! including a handle and a tool coupled to the handle. The tool head includes a frame that supports a first engagement panel and a second engagement panel, with each panel disposed on an underside of the frame. The tool also includes a cable that extends between the tool head and the handle and that is coupled to the first engagement panel and the second engagement panel. An actuator mechanism is coupled to the cable and is manipulatable to move at least one of the first engagement panel and the second engagement panel via the cable relative to the frame to selectively engage and disengage a mop pad relative to the tool head.

Abstract: A method for holding a vehicle at a standstill includes a first phase in which the brake pressure at the wheel brakes is retained so that the vehicle is held automatically by the service brake, and the braking force is then transferred to a parking brake so that in a second phase the vehicle is held solely by the parking brake. A risk inherent in this transfer is that the vehicle may begin to slip. The distance over which the vehicle slides in uncontrolled fashion can be made substantially shorter if, in the second phase in which the vehicle is being held by the parking brake, the movement of the vehicle is monitored by sensors, and brake pressure is automatically built up by way of an actuator as soon as the fact that the vehicle is rolling away has been detected.

Abstract: The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 10?10 mol/l. The CDR sequences according to the invention are suitable in particular for producing recombinant fragments (such as scFv fragments or bispecific antibodies) and for immunotargeting, due to the high affinity thereof.

Abstract: The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumour diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.

Abstract: A method for holding a vehicle at a standstill includes a first phase in which the brake pressure at the wheel brakes is retained so that the vehicle is held automatically by the service brake, and the braking force is then transferred to a parking brake so that in a second phase the vehicle is held solely by the parking brake. A risk inherent in this transfer is that the vehicle may begin to slip. The distance over which the vehicle slides in uncontrolled fashion can be made substantially shorter if, in the second phase in which the vehicle is being held by the parking brake, the movement of the vehicle is monitored by sensors, and brake pressure is automatically built up by way of an actuator as soon as the fact that the vehicle is rolling away has been detected.

Abstract: The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumour cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumour cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumour cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.

Abstract: A rotary elastic coupling is fitted with an inner ring and with an outer ring surrounding the inner ring around the periphery by forming an annular slit. An elastomer is provided in the annular slit, which is vulcanized or glued to the inner ring and to the outer ring and fills up the annular slit substantially or completely. The annular slit is meander-shaped around the periphery of the coupling so that radially outward protrusions of the inner ring undercut radially inward protrusions of the outer ring. Around the periphery of the coupling, a relief opening is provided in the elastomer on both sides of the protrusions of the inner ring and on both sides of the protrusions of the outer ring.